Thrombocytopenia - Market Insight, Epidemiology And Market Forecast - 2032

Thrombocytopenia - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight’s ‘Thrombocytopenia - Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of Thrombocytopenia historical and forecasted epidemiology as well as the Thrombocytopenia market trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Thrombocytopenia market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Thrombocytopenia market size. The report also covers Thrombocytopenia procedure, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019–2032

Thrombocytopenia Understanding

Thrombocytopenia Overview

Thrombocytopenia is a condition in which the blood has an abnormal number of blood cell fragments called platelets. Platelets are made in the bone marrow along with other kinds of blood cells. They travel through the blood vessels and stick together (clot) to stop any bleeding that may happen if a blood vessel is damaged. Platelets are also called thrombocytes because a clot is also called a thrombus. When a patient’s blood has few platelets, mild-to-serious bleeding can occur inside the body (internal bleeding), underneath the skin, or from the skin’s surface.

Continued in the report…

Causes of Thrombocytopenia

• Thrombocytopenia has many etiologies, such as bone marrow failure, bone marrow suppression (e.g., from medication, chemotherapy, or irradiation), chronic alcohol abuse, myelodysplastic syndrome, autoimmune syndromes, etc.

Thrombocytopenia Indications

• Immune thrombocytopenic purpura (ITP): An acquired immune-mediated disorder characterized by isolated thrombocytopenia and the absence of other conditions or agents known to induce thrombocytopenia. The incidence is 100 cases per 1 million persons annually, and approximately 50% of cases occur in children. Immune thrombocytopenic purpura in children often resolves spontaneously but is more insidious and chronic in adults. The risk of bleeding correlates to the severity of thrombocytopenia. Patients may present without symptoms, minimal bleeding, or serious hemorrhage (e.g., mucosal, intracranial, gastrointestinal, genitourinary). Older patients, patients on antiplatelet therapy, and patients with comorbid conditions may have severe bleeding manifestations.
• Drug-induced thrombocytopenia: One of the most common types of thrombocytopenia in the outpatient setting is drug-induced thrombocytopenia. An epidemiologic study from Europe and the US showed an annual incidence of 10 cases/1 million persons, but numbers could be higher in older and hospitalized patients. Drug-induced thrombocytopenia is suspected in all patients presenting with an acute drop in platelet count. Most patients with drug-induced thrombocytopenia have moderate-to-severe thrombocytopenia reaching a nadir platelet count of 20 × 103/μL. During treatment, physicians should ask specific questions about the use of any medications, including nutritional supplements and over-the-counter remedies being taken by the patient. Quinine is a common cause of drug-induced thrombocytopenia and is often missed in the patient’s history.

Continued in the report…..

Thrombocytopenia Epidemiology

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Thrombocytopenic Purpura (TTP), Total Cases of Immune Thrombocytopenia (ITP), Total Cases of Thrombocytopenia in Chronic Liver Disease, Total Cases of Chemotherapy-induced Thrombocytopenia, Total Number of Cases of Heparin-induced Thrombocytopenia, and Total Cases of Thrombocytopenia scenario in the 7MM covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

• In 2021, the total cases of Thrombocytopenia in the 7MM countries were 2,608,095, and these cases are anticipated to increase during the study period. The US accounted for 1,045,247 cases of Thrombocytopenia in 2021.
• Among the European countries, Germany had the highest number of cases of Thrombocytopenia in 2021, i.e., 453,441 cases, followed by the UK which had 269,422 cases in 2021. On the other hand, Italy had the lowest number of cases of Thrombocytopenia, i.e. 127,166 cases in 2021.
• The highest cases of TTP were seen in the US which accounted for 6,002 cases in 2021.
• Japan, in 2021, accounted for 58,261 cases of Chemotherapy-induced Thrombocytopenia, which is expected to increase during the study period.
• The maximum number of cases of Heparin-induced Thrombocytopenia in 2021 were recorded in Germany out of all the EU-5 countries and Spain accounted for the least number of cases.

Thrombocytopenia Drug Chapters

Thrombocytopenia Emerging Drugs

Rilzabrutinib: Sanofi/Principia Biopharma

Rilzabrutinib (PRN-1008) is an orally administered reversible covalent inhibitor of Bruton tyrosine kinase (BTK). BTK is an essential signaling element downstream of the B-cell receptor (BCR), Fc-gamma receptor, and Fc-epsilon receptor pathways. BTK activation is critical for B-cell activation and maturation. BTK also regulates antibody-mediated activation of other immune cells, such as macrophages, neutrophils, and mast cells, through Fc receptor signaling. The drug candidate is a fast-acting, orally available therapy that could effectively and safely modulate B-cell function without depleting the B-cell and is expected to be a major advancement in treating autoimmune and inflammatory diseases.

Product details in the report…

TAK-755: Baxalta/Takeda

TAK-755 (BAX930/SHP655) is a human recombinant ADAMTS13, the plasma metalloprotease that regulates the von Willebrand factor (VWF) multimers. The drug provide an alternative to the current replacement of ADAMTS13 using large volumes of fresh frozen plasma that contain variable amounts of ADAMTS13 and typically require 2 h or more for the preparation and infusion. In contrast, BAX 930 can be quickly reconstituted and may thus be suitable for treatment in the patient’s home. ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats-13) cleaves VWF. This process is essential for hemostasis. Severe deficiency of plasma ADAMTS13 activity, most commonly resulting from autoantibodies against ADAMTS13, causes thrombotic thrombocytopenic purpura.

Products detail in the report…

Efgartigimod: Argenx

Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases and was designed to exploit the natural interaction between IgG antibodies and the recycling receptor FcRn Argenx, designed efgartigimod to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications, namely multiple sclerosis, ITP, systemic lupus erythematosus, myasthenia gravis, and skin-blistering diseases.

Product details in the report…

Thrombocytopenia Market Outlook

Thrombocytopenia is a condition in which the blood has a lower than the normal platelet count. When a patient’s blood has too few platelets, mild to serious bleeding can occur. Bleeding can be internal or underneath the skin, or external.

The approved therapies for treating thrombocytopenia in the US include MULPLETA, DOPTELET, TAVALISSE, PROMACTA, NPLATE, CABLIVI, GAMMAPLEX, OCTAGAM, RHOPHYLAC, and PRIVIGEN. These therapies are approved for various patient groups; for example, MULPLETA and DOPTELET are approved for thrombocytopenia in chronic liver disease, PROMACTA is approved for chronic immune (idiopathic) thrombocytopenic purpura (ITP).

The approved therapies in the EU include MULPLETA/MULPLEO (lusutrombopag), DOPTELET (avatrombopag), TAVALISSE/TAVLESSE (fostamatinib), PROMACTA/REVOLADE (eltrombopag), NPLATE/ROMIPLATE (romiplostim), and CABLIVI (caplacizumabum).

OCTAGAM, RHOPHYLAC, and PRIVIGEN are the immunoglobulins approved in the EU to treat immune thrombocytopenic purpura.

The approved medications in Japan for the treatment of thrombocytopenia include various etiologies like MULPLETA/ MULPLEO (lusutrombopag), PROMACTA/REVOLADE (eltrombopag), NPLATE/ROMIPLATE (romiplostim), and RITUXAN (rituximab).

Continued in the report…..

Key Findings

• The market size of Thrombocytopenia in the 7MM was observed to be USD 4,412 million in 2021.
• In 2021, the US has the largest Thrombocytopenia market size of USD 2,447 million among the 7MM countries.
• Among the EU-5 countries, Germany had the highest market size for Thrombocytopenia in 2021, i.e., USD 431 million. The lowest market size was estimated in France with USD 242 million in 2021.
• In Japan, the market size for Thrombocytopenia was observed to be USD 328 million in 2021.

The United States Market Outlook

This section provides the total Thrombocytopenia market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Thrombocytopenia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Thrombocytopenia market size and market size by therapies in Japan are provided.

Thrombocytopenia Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Thrombocytopenia market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Thrombocytopenia market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Thrombocytopenia Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, merger, licensing, and patent details for Thrombocytopenia emerging therapies.

Reimbursement Scenario in Thrombocytopenia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive market Intelligence analysis of the Thrombocytopenia market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers a descriptive overview of Thrombocytopenia, explaining its procedure, types, indications, and currently available therapies.
• Comprehensive insight has been provided into Thrombocytopenia epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Thrombocytopenia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Thrombocytopenia market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Thrombocytopenia market.

Report Highlights

• The robust pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the Thrombocytopenia market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Thrombocytopenia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition using Thrombocytopenia.
• Major players are involved in developing therapies for Thrombocytopenia. The launch of emerging therapies will significantly impact the Thrombocytopenia market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Thrombocytopenia Report Insights

• Patient Population
• Therapeutic Approaches
• Thrombocytopenia Pipeline Analysis
• Thrombocytopenia Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Thrombocytopenia Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Thrombocytopenia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Thrombocytopenia Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT analysis

Key Questions

Market Insights:

• What was the Thrombocytopenia market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Thrombocytopenia total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Thrombocytopenia market size during the forecast period (2022–2032)?
• At what CAGR, the Thrombocytopenia market is expected to grow at the 7MM level during the forecast period (2022–2032)?
• What would be the Thrombocytopenia market outlook across the 7MM during the forecast period (2022–2032)?
• What would be the Thrombocytopenia market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the risk, burdens, and unmet needs of Thrombocytopenia?
• What is the historical Thrombocytopenia patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Thrombocytopenia at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Thrombocytopenia?
• Out of the above-mentioned countries, which country would have the highest cases of Thrombocytopenia during the forecast period (2022–2032)?
• At what CAGR are these cases expected to grow across the 7MM during the forecast period (2022–2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current treatment practices in Thrombocytopenia along with the approved therapy?
• What are the current treatment guidelines for Thrombocytopenia?
• What are the Thrombocytopenia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for Thrombocytopenia?
• How many emerging therapies are in the mid-stage and late stages of development for Thrombocytopenia?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Thrombocytopenia therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Thrombocytopenia and their status?
• What are the key designations that have been granted for the emerging therapies for Thrombocytopenia?
• What are the 7MM historical and forecasted market of Thrombocytopenia?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving Thrombocytopenia.
• To understand the future market competition in the Thrombocytopenia market and an insightful review of the market.
• Organize sales and marketing efforts by identifying the best opportunities for Thrombocytopenia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Thrombocytopenia market.
• To understand the future market competition in the Thrombocytopenia market.